|
CA204125A
(en)
|
|
1920-09-21 |
Sylvester Pratt Edwin |
Gramophone operated toy
|
|
US819826A
(en)
|
1905-12-14 |
1906-05-08 |
Frank R Welcher |
Stanchion.
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
CZ302706B6
(cs)
|
1998-12-23 |
2011-09-14 |
Pfizer Inc. |
Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
CZ301498B6
(cs)
|
1999-02-22 |
2010-03-24 |
Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) |
C-21 modifikované epothilony
|
|
US7629360B2
(en)
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
JP2003520828A
(ja)
|
2000-01-27 |
2003-07-08 |
ジェネティクス インスティテュート，エルエルシー |
Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
|
|
US7041499B2
(en)
|
2001-12-12 |
2006-05-09 |
University Of North Texas Health Science Center |
Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
|
|
CA2752124A1
(en)
*
|
2002-05-17 |
2003-11-27 |
Celgene Corporation |
Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
BRPI0315295C1
(pt)
|
2002-10-17 |
2021-05-25 |
Genmab As |
anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
|
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
|
US20050025763A1
(en)
|
2003-05-08 |
2005-02-03 |
Protein Design Laboratories, Inc. |
Therapeutic use of anti-CS1 antibodies
|
|
US6958115B2
(en)
|
2003-06-24 |
2005-10-25 |
The United States Of America As Represented By The Secretary Of The Navy |
Low temperature refining and formation of refractory metals
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
NZ574979A
(en)
|
2006-08-07 |
2012-06-29 |
Abbott Biotherapeutics Corp |
Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
|
|
CN101534860B
(zh)
*
|
2006-08-07 |
2013-03-27 |
艾伯特生物治疗学公司 |
使用抗cs1-抗体治疗多发性骨髓瘤的组合物和方法
|
|
AU2007281684C1
(en)
*
|
2006-08-07 |
2013-12-19 |
Abbvie Biotherapeutics Inc. |
Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
|
|
EP2069478A2
(en)
|
2006-08-07 |
2009-06-17 |
PDL BioPharma, Inc. |
Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
|
|
EP2361263A1
(en)
|
2008-10-31 |
2011-08-31 |
Abbott Biotherapeutics Corp. |
Use of anti-cs1 antibodies for treatment of rare lymphomas
|
|
BRPI1007855B1
(pt)
|
2009-05-19 |
2020-03-10 |
Celgene Corporation |
Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona
|
|
EP2493485A1
(en)
|
2009-10-30 |
2012-09-05 |
University Of Arkansas For Medical Science |
Use of autologous effector cells for treatment of multiple myeloma
|
|
WO2011053322A1
(en)
|
2009-10-30 |
2011-05-05 |
University Of Arkansas For Medical Science |
Use of autologous effector cells and antibodies for treatment of multiple myeloma
|
|
US9506481B1
(en)
|
2013-01-31 |
2016-11-29 |
Daniel Theobald |
High force hydraulic actuator
|
|
US20160331698A1
(en)
*
|
2014-01-13 |
2016-11-17 |
University Of Central Florida Research Foundation, Inc. |
Fullerene compounds as antioxidant therapy
|
|
AU2015305449B2
(en)
|
2014-08-22 |
2021-05-06 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
|
AU2015339012B2
(en)
*
|
2014-10-31 |
2020-11-05 |
Abbvie Biotherapeutics Inc. |
Anti-CS1 antibodies and antibody drug conjugates
|
|
RS62352B1
(sr)
*
|
2015-06-29 |
2021-10-29 |
Bristol Myers Squibb Co |
Imunoterapijski režimi doziranja koji obuhvataju pomalidomid i anti-cs1 antitelo za lečenje kancera
|